Developer docs
API playgroundTry for free, no card

Search company profiles

inbiose

Full company profile

uuid0002gfq

Namestring
inbiose
Legal namestring
Inbiose NV
Websiteurl
inbiose.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Inbiose is a Belgian B2B biotechnology company founded in 2013 as a Ghent University spin-off that develops and manufactures specialty carbohydrate ingredients—primarily Human Milk Oligosaccharides (HMOs)—using precision fermentation and synthetic biology. Operating from Zwijnaarde, Belgium with approximately 50 employees, the company serves four primary application segments: early life nutrition (infant formula and toddler products), dietary supplements and medical nutrition, functional food and beverages, and pet nutrition/animal feed. Its commercial portfolio comprises six individual HMO ingredients (GlycoActive™ 2'-FL, 3'-FL, 3'-SL, 6'-SL, LNT, LNnT) and three proprietary blends (3-HMO, 5-HMO, and 6-HMO) targeting gut, immune, metabolic, and cognitive health outcomes.

The company's core technology is the proprietary GlycoActives® platform, which combines a microbial strain library of 70,000+ strains, a 2,000+ enzyme library, capability to develop 30+ glycans, automated robotic high-throughput screening, and machine learning-driven strain optimization. This stack enables a documented 12-month molecule-to-pilot-scale cycle. Manufacturing is asset-light: in-house lab-scale fermentation for optimization is paired with external partners for scale-up to 66 metric tons. Multi-jurisdiction regulatory clearances—FDA GRAS for five HMOs, EFSA Novel Food approval, full Chinese approval for 2'-FL, and Canadian authorization for 2'-FL (May 2025)—form the regulatory backbone of the business.

Inbiose operates a sales-led go-to-market with direct enterprise engagement, inside sales for mid-market, and event-driven demand generation at industry conferences (ESPGHAN, Vitafoods Europe, Future Food Tech). Revenue is generated via quote-based, multi-year B2B ingredient supply contracts with flexible MOQs for both pilot and commercial-scale volumes; pricing is not publicly disclosed. The company has raised €15 million in non-dilutive debt financing from the European Investment Bank (2023), maintains a strategic relationship with Danone Ventures, and in April 2025 transitioned Dirk Abeel from CCO to CEO while co-founder Prof. Wim Soetaert moved to Executive Chairman, signaling a shift from R&D-led to commercial-scaling focus.

Short descriptiontext

Inbiose is a Belgian B2B biotech company that produces nature-identical Human Milk Oligosaccharides via precision fermentation for B2B customers in infant nutrition, dietary supplements, functional food and beverage, and pet nutrition markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGhent, Belgium
HQ citystring
Ghent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
human milk oligosaccharides, precision fermentation ingredients, specialty carbohydrate manufacturing, synthetic biology platform, HMO ingredient supplier
Industry3 codes
PRIMARYEUAAAIAJ
Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements
NAICS code1 code
  • Food Manufacturing311
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Biotechnology Ingredients (Human Milk Oligosaccharides)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1HMO Ingredient Sales
TypeOne Time License
Description

Sale of Human Milk Oligosaccharide ingredients (individual HMOs and proprietary blends) to manufacturers of infant nutrition, dietary supplements, functional foods, beverages, pet nutrition, and animal feed products.

inbiose.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Quote-based commercial pricing tailored to volume, format, and timeline
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Pricing determined by consultation. Offers flexible MOQs supporting both pilot prototyping and high-volume commercial production.

inbiose.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1GlycoActives
Description

Proprietary platform using synthetic biology and precision fermentation to deliver bioactive carbohydrates including HMOs for health ingredients.

inbiose.com
+1 more record
Core offering1 text field

Inbiose develops and manufactures nature-identical Human Milk Oligosaccharide (HMO) ingredients and proprietary multi-HMO blends using its proprietary GlycoActives® precision fermentation platform. The company sells six individual HMO ingredients (2'-FL, 3-FL, 3'-SL, 6'-SL, LNT, LNnT) and proprietary blends to B2B customers in infant nutrition, dietary supplements, functional food & beverage, medical nutrition, pet nutrition, and animal feed markets worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Regulatory clearance in 4 major markets (US, EU, China, Canada)
+2 more records
Product overview1 text field

Inbiose's product portfolio centers on its GlycoActives® technology platform, which enables precision fermentation production of human milk oligosaccharides (HMOs). The offering comprises six individual HMO ingredients (GlycoActive™ 2FL, 3SL, LNT, 3FL, 6SL, and LNnT) as single-pure ingredients for targeted formulations, alongside three proprietary GlycoActives™ Blends (3 HMO, 5 HMO, and 6 HMO blends) combining multiple glycans for synergistic gut, cognition, and immune health effects. All products are produced via sustainable precision fermentation, are GRAS/EFSA-approved, and target applications across early life nutrition, dietary supplements, functional foods and beverages, pet nutrition, and animal feed.

Product and service9 records
1GlycoActive™ 2FL (2'-Fucosyllactose)
CategoryCore HMO Ingredient
Description

The most abundant HMO in human milk, used for immune, gut, and metabolic health support across infant nutrition, dietary supplements, and functional foods.

2GlycoActive™ 3SL (3'-Sialyllactose)
CategoryCore HMO Ingredient
Description

Sialylated HMO with immune health relevance, supporting microbiome modulation and cognitive development.

3GlycoActive™ LNT (Lacto-N-tetraose)
CategoryCore HMO Ingredient
Description

Core neutral HMO found in high concentration in breast milk, supporting gut barrier function and beneficial bacteria colonization.

4GlycoActive™ 3FL (3-Fucosyllactose)
CategoryCore HMO Ingredient
Description

HMO that rises significantly during lactation, supporting gut health and immune function.

5GlycoActive™ 6SL (6'-Sialyllactose)
CategoryCore HMO Ingredient
Description

Most abundant sialylated HMO in milk, supporting immune health and cognitive development.

6GlycoActive™ LNnT (Lacto-N-neotetraose)
CategoryCore HMO Ingredient
Description

HMO with unique prebiotic profile, supporting gut microbiota balance and immune function.

73 HMO Blend (Gut & Immune Blend)
CategoryProprietary HMO Blend
Description

Proprietary blend of 3 HMOs designed for gut and immune health applications, combining multiple glycans for synergistic effects.

85 HMO Blend (Gut, Cognition & Immune Blend)
CategoryProprietary HMO Blend
Description

Proprietary blend of 5 HMOs targeting gut health, cognitive function, and immune support, designed for advanced formulation needs.

96 HMO Blend (Gut, Cognition & Immune Blend)
CategoryProprietary HMO Blend
Description

Comprehensive proprietary blend of 6 HMOs for gut, cognition, and immune health, representing the most complete HMO formulation in the portfolio.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

EIC co-organized the Start & Scale-up Event with Impact Circle (Tomorrowland) where Inbiose participated. EIC supports European innovation and scale-ups in biotech and sustainable food sectors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

Impact Circle, the sustainability initiative of Tomorrowland festival, co-organized a Start & Scale-up Event with EIC where Inbiose pitched and networked with major corporations. Engaged in discussions about co-creating environmental and societal impact through strategic partnerships.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-24
Description

Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Fermentation-based food ingredients company producing lactic acid, algae-based ingredients, and functional food components. Comparable as a precision-fermentation platform targeting food, nutrition, and health applications.

TypeEmerging player
Description

Producer of chicory-derived inulin and prebiotic fibers used in gut-health formulations. Comparable as a supplier of prebiotic and gut-health ingredients to supplement and food manufacturers.

TypeBroad incumbent
Description

Global nutrition and ingredients giant that absorbed HMO pioneer Glycom in 2020. Competes with Inbiose across HMOs, infant nutrition ingredients, and precision-fermented bioactives, with materially greater scale and capital.

TypeDirect peer
Description

Pioneering HMO producer acquired by DSM in 2020 for ~€765M. Closest historical direct comparable in scale of HMO business, regulatory breadth, and precision-fermentation technology at acquisition time.

TypeEmerging player
Description

Biotech developing probiotic and microbiome-targeted ingredients for dietary supplements and functional foods. Comparable in applying microbiome science to commercial ingredient offerings across overlapping customer segments.

TypeBroad incumbent
Description

Merged bioscience platform combining microbial fermentation leadership (Novozymes) with Chr. Hansen's HMO programs (including the former Jennewein acquisition). Directly comparable fermentation-driven ingredient production serving similar CPG and nutrition customers.

7ZuChem
TypeDirect peer
Description

US-based specialty carbohydrate producer using fermentation and biocatalysis for rare sugars and HMOs. Most directly comparable in technology stack (fermentation-based specialty carbs) and target markets (food, supplement, infant nutrition).

TypeOthers
Description

Fermentation-derived amino acids, nucleotides, and bioactive ingredients for nutrition and pharma. Comparable as a fermentation-based specialty ingredient manufacturer serving overlapping dietary supplement and food customers.

9Jennewein Biotechnologie
TypeDirect peer
Description

Pioneer HMO specialist focused on precision-fermented human milk oligosaccharides for infant nutrition. Now part of Chr. Hansen / Novonesis but historically a direct comparable specialty HMO producer targeting the same customers as Inbiose.

TypeBroad incumbent
Description

Chemicals and nutrition major with HMO programs targeted at infant formula and dietary supplements. Operates at vastly larger scale with broader ingredient portfolios overlapping Inbiose's precision-fermentation offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

inbiose

Specialty Biotechnology Ingredients (Human Milk Oligosaccharides)inbiose.com

Inbiose is a Belgian B2B biotech company that produces nature-identical Human Milk Oligosaccharides via precision fermentation for B2B customers in infant nutrition, dietary supplements, functional food and beverage, and pet nutrition markets.

What inbiose does

Inbiose is a Belgian B2B biotechnology company founded in 2013 as a Ghent University spin-off that develops and manufactures specialty carbohydrate ingredients—primarily Human Milk Oligosaccharides (HMOs)—using precision fermentation and synthetic biology. Operating from Zwijnaarde, Belgium with approximately 50 employees, the company serves four primary application segments: early life nutrition (infant formula and toddler products), dietary supplements and medical nutrition, functional food and beverages, and pet nutrition/animal feed. Its commercial portfolio comprises six individual HMO ingredients (GlycoActive™ 2'-FL, 3'-FL, 3'-SL, 6'-SL, LNT, LNnT) and three proprietary blends (3-HMO, 5-HMO, and 6-HMO) targeting gut, immune, metabolic, and cognitive health outcomes.

The company's core technology is the proprietary GlycoActives® platform, which combines a microbial strain library of 70,000+ strains, a 2,000+ enzyme library, capability to develop 30+ glycans, automated robotic high-throughput screening, and machine learning-driven strain optimization. This stack enables a documented 12-month molecule-to-pilot-scale cycle. Manufacturing is asset-light: in-house lab-scale fermentation for optimization is paired with external partners for scale-up to 66 metric tons. Multi-jurisdiction regulatory clearances—FDA GRAS for five HMOs, EFSA Novel Food approval, full Chinese approval for 2'-FL, and Canadian authorization for 2'-FL (May 2025)—form the regulatory backbone of the business.

Inbiose operates a sales-led go-to-market with direct enterprise engagement, inside sales for mid-market, and event-driven demand generation at industry conferences (ESPGHAN, Vitafoods Europe, Future Food Tech). Revenue is generated via quote-based, multi-year B2B ingredient supply contracts with flexible MOQs for both pilot and commercial-scale volumes; pricing is not publicly disclosed. The company has raised €15 million in non-dilutive debt financing from the European Investment Bank (2023), maintains a strategic relationship with Danone Ventures, and in April 2025 transitioned Dirk Abeel from CCO to CEO while co-founder Prof. Wim Soetaert moved to Executive Chairman, signaling a shift from R&D-led to commercial-scaling focus.

inbiose firmographics

Firmographics
Name
inbiose
Legal name
Inbiose NV
Website
https://inbiose.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Inbiose is a Belgian B2B biotech company that produces nature-identical Human Milk Oligosaccharides via precision fermentation for B2B customers in infant nutrition, dietary supplements, functional food and beverage, and pet nutrition markets.
Ownership category
akta.pro rank

inbiose industry classification

Industry
Product category
Specialty Biotechnology Ingredients (Human Milk Oligosaccharides)
NAICS
Food Manufacturing (311)
SIC
Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYEUAAAIAJ
Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)
SECONDARYCRADAGAF
Probiotics & Digestive Health Supplements

Keywords

  • Human milk oligosaccharides
  • Precision fermentation ingredients
  • Specialty carbohydrate manufacturing
  • Synthetic biology platform
  • HMO ingredient supplier

Where inbiose is headquartered

Location

Headquarters

HQ city
Ghent
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

inbiose business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. HMO Ingredient Sales: Sale of Human Milk Oligosaccharide ingredients (individual HMOs and proprietary blends) to manufacturers of infant nutrition, dietary supplements, functional foods, beverages, pet nutrition, and animal feed products.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractQuote-based commercial pricing tailored to volume, format, and timeline

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

inbiose product offering

Product offering

Core offering

Inbiose develops and manufactures nature-identical Human Milk Oligosaccharide (HMO) ingredients and proprietary multi-HMO blends using its proprietary GlycoActives® precision fermentation platform. The company sells six individual HMO ingredients (2'-FL, 3-FL, 3'-SL, 6'-SL, LNT, LNnT) and proprietary blends to B2B customers in infant nutrition, dietary supplements, functional food & beverage, medical nutrition, pet nutrition, and animal feed markets worldwide.

Product overview

Inbiose's product portfolio centers on its GlycoActives® technology platform, which enables precision fermentation production of human milk oligosaccharides (HMOs). The offering comprises six individual HMO ingredients (GlycoActive™ 2FL, 3SL, LNT, 3FL, 6SL, and LNnT) as single-pure ingredients for targeted formulations, alongside three proprietary GlycoActives™ Blends (3 HMO, 5 HMO, and 6 HMO blends) combining multiple glycans for synergistic gut, cognition, and immune health effects. All products are produced via sustainable precision fermentation, are GRAS/EFSA-approved, and target applications across early life nutrition, dietary supplements, functional foods and beverages, pet nutrition, and animal feed.

Differentiator

Problem solved

Functional benefit

Brands

  • GlycoActives: Proprietary platform using synthetic biology and precision fermentation to deliver bioactive carbohydrates including HMOs for health ingredients.
  • GlycoActive™ HMOs

Products and services

  • GlycoActive™ 2FL (2'-Fucosyllactose) The most abundant HMO in human milk, used for immune, gut, and metabolic health support across infant nutrition, dietary supplements, and functional foods.
  • GlycoActive™ 3SL (3'-Sialyllactose) Sialylated HMO with immune health relevance, supporting microbiome modulation and cognitive development.
  • GlycoActive™ LNT (Lacto-N-tetraose) Core neutral HMO found in high concentration in breast milk, supporting gut barrier function and beneficial bacteria colonization.
  • GlycoActive™ 3FL (3-Fucosyllactose) HMO that rises significantly during lactation, supporting gut health and immune function.
  • GlycoActive™ 6SL (6'-Sialyllactose) Most abundant sialylated HMO in milk, supporting immune health and cognitive development.
  • GlycoActive™ LNnT (Lacto-N-neotetraose) HMO with unique prebiotic profile, supporting gut microbiota balance and immune function.
  • 3 HMO Blend (Gut & Immune Blend) Proprietary blend of 3 HMOs designed for gut and immune health applications, combining multiple glycans for synergistic effects.
  • 5 HMO Blend (Gut, Cognition & Immune Blend) Proprietary blend of 5 HMOs targeting gut health, cognitive function, and immune support, designed for advanced formulation needs.
  • 6 HMO Blend (Gut, Cognition & Immune Blend) Comprehensive proprietary blend of 6 HMOs for gut, cognition, and immune health, representing the most complete HMO formulation in the portfolio.

Quantifiable outcome

  • Regulatory clearance in 4 major markets (US, EU, China, Canada)
  • +2 more outcomes

Companies that use inbiose

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

inbiose technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

inbiose partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • European Innovation Council (EIC)coreStrategic or Co-development Partner · 24 July 2025EIC co-organized the Start & Scale-up Event with Impact Circle (Tomorrowland) where Inbiose participated. EIC supports European innovation and scale-ups in biotech and sustainable food sectors.
  • Impact Circle (Tomorrowland)coreStrategic or Co-development Partner · 24 July 2025Impact Circle, the sustainability initiative of Tomorrowland festival, co-organized a Start & Scale-up Event with EIC where Inbiose pitched and networked with major corporations. Engaged in discussions about co-creating environmental and societal impact through strategic partnerships.
  • The Coca-Cola CompanyminorStrategic or Co-development Partner · 24 July 2025Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.
  • AB InBevminorStrategic or Co-development Partner · 24 July 2025Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.
  • Procter & GambleminorStrategic or Co-development Partner · 24 July 2025Invited Inbiose to participate in the Start & Scale-up Event co-organized by EIC and Impact Circle. Represents potential strategic partnership opportunity for innovation collaboration.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

inbiose competitors and assessment

Company assessment

Broad incumbents

  • Corbion: Fermentation-based food ingredients company producing lactic acid, algae-based ingredients, and functional food components. Comparable as a precision-fermentation platform targeting food, nutrition, and health applications.
  • dsm-firmenich: Global nutrition and ingredients giant that absorbed HMO pioneer Glycom in 2020. Competes with Inbiose across HMOs, infant nutrition ingredients, and precision-fermented bioactives, with materially greater scale and capital.
  • Novonesis (formerly Novozymes + Chr. Hansen): Merged bioscience platform combining microbial fermentation leadership (Novozymes) with Chr. Hansen's HMO programs (including the former Jennewein acquisition). Directly comparable fermentation-driven ingredient production serving similar CPG and nutrition customers.
  • BASF: Chemicals and nutrition major with HMO programs targeted at infant formula and dietary supplements. Operates at vastly larger scale with broader ingredient portfolios overlapping Inbiose's precision-fermentation offerings.

Emerging players

  • Sensus (Royal Cosun): Producer of chicory-derived inulin and prebiotic fibers used in gut-health formulations. Comparable as a supplier of prebiotic and gut-health ingredients to supplement and food manufacturers.
  • AB Biotics: Biotech developing probiotic and microbiome-targeted ingredients for dietary supplements and functional foods. Comparable in applying microbiome science to commercial ingredient offerings across overlapping customer segments.

Direct peers

  • Glycom (now part of dsm-firmenich): Pioneering HMO producer acquired by DSM in 2020 for ~€765M. Closest historical direct comparable in scale of HMO business, regulatory breadth, and precision-fermentation technology at acquisition time.
  • ZuChem: US-based specialty carbohydrate producer using fermentation and biocatalysis for rare sugars and HMOs. Most directly comparable in technology stack (fermentation-based specialty carbs) and target markets (food, supplement, infant nutrition).
  • Jennewein Biotechnologie: Pioneer HMO specialist focused on precision-fermented human milk oligosaccharides for infant nutrition. Now part of Chr. Hansen / Novonesis but historically a direct comparable specialty HMO producer targeting the same customers as Inbiose.

Others

  • Kyowa Hakko Bio: Fermentation-derived amino acids, nucleotides, and bioactive ingredients for nutrition and pharma. Comparable as a fermentation-based specialty ingredient manufacturer serving overlapping dietary supplement and food customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

inbiose social profiles

Digital presence

inbiose compliance and trust

Trust signal

Compliance4 records

inbiose financial estimates

Financial estimate

Revenue estimate

Valuation estimate

inbiose leadership team

Management profile

Number of profiles

Profiles6 records

inbiose funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

inbiose M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about inbiose

What does inbiose do?

Inbiose develops and manufactures nature-identical Human Milk Oligosaccharide (HMO) ingredients and proprietary multi-HMO blends using its proprietary GlycoActives® precision fermentation platform. The company sells six individual HMO ingredients (2'-FL, 3-FL, 3'-SL, 6'-SL, LNT, LNnT) and proprietary blends to B2B customers in infant nutrition, dietary supplements, functional food & beverage, medical nutrition, pet nutrition, and animal feed markets worldwide.

Is inbiose a public or private company?

inbiose is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was inbiose founded?

inbiose was founded in 2013. It employs 51 to 100 people.

Where is inbiose based?

inbiose is headquartered in Ghent, Belgium, in the Europe region.

How does inbiose make money?

One revenue line is on record: HMO Ingredient Sales.

Who are inbiose's main competitors?

Broad incumbents on record are Corbion, dsm-firmenich, Novonesis (formerly Novozymes + Chr. Hansen) and BASF. Emerging players are Sensus (Royal Cosun) and AB Biotics. Direct peers are Glycom (now part of dsm-firmenich), ZuChem and Jennewein Biotechnologie. Kyowa Hakko Bio is listed as an others.

Does inbiose have an API?

No public API is recorded for inbiose.

What industry is inbiose in?

inbiose's product category is Specialty Biotechnology Ingredients (Human Milk Oligosaccharides). Its primary akta.pro industry code is EUAAAIAJ, Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors), with a secondary code of CRADAOAI, Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts). Its NAICS code is 311 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInbiose beantragt die GRAS-Zulassung der FDA für vier neue humane Milch-OligosaccharideBelgian biotech company Inbiose has filed a GRAS (Generally Recognized As Safe) application with the FDA for four human milk oligosaccharides (6'-Sialyllactose, 3-Sialyllactose, Lacto-N-Tetraose, and Lacto-N-neoTetraose), with plans to submit corresponding Novel Food applications to the European Food Safety Authority in the coming weeks. The company expects regulatory approval in 2022 and is organizing industrial production for delivery to customers in infant formula, dietary supplements, and functional foods and beverages. Industry observers project the HMO market could reach €500 million by 2025 and grow beyond €1 billion, with applications extending beyond infant nutrition to broader health benefits.PR NewswireInbiose applies for FDA GRAS approval of four new Human Milk OligosaccharidesInbiose, a Belgian biotech company specializing in Human Milk Oligosaccharides, has submitted a GRAS application to the US FDA for four HMOs (6'-Sialyllactose, 3-Sialyllactose, Lacto-N-Tetraose, and Lacto-N-neoTetraose), with plans to file for EU Novel Food approval shortly. The company expects to obtain regulatory approval in 2022 and is organizing industrial production for deliveries to customers in infant nutrition, dietary supplements, and functional food and beverages. Industry watchers project the HMO market to reach €500 million by 2025 and grow beyond €1 billion, driven by applications in immunity, gut health, and brain health.PR NewswireInbiose solicita la aprobación GRAS de la FDA de cuatro nuevos oligosacáridos de leche maternaInbiose, a Belgian biotechnology company focused on human milk oligosaccharides (HMOs), has submitted a GRAS application to the US FDA for four specific HMOs (6'-Sialilactosa, 3-Sialilactosa, Lacto-N-Tetraosa, and Lacto-N-neoTetraosa), with plans to also seek Novel Food approval from the European Commission. The company expects to obtain regulatory clearance in 2022 and is organizing industrial production for delivery to customers in infant nutrition, dietary supplements, and functional foods and beverages. Industry observers project the HMO market could reach 500 million euros by 2025 and grow to over 1 billion euros thereafter.PR NewswireHMO Market Size Worth USD 71.2 Billion by 2025 | CAGR: 21.9%: Grand View Research, Inc.Grand View Research released a market report projecting the global human milk oligosaccharides (HMO) market to reach USD 71.2 billion by 2025, growing at a CAGR of 21.9% during the forecast period, driven by rising consumer awareness of infant health and increased investments in emerging economies. The report highlights that North America held over 80% revenue share in 2017 due to early product adoption and the presence of infant formula companies, while the infant formula segment is expected to witness the fastest growth. Key market activities include product launches and partnerships by major companies such as Inbiose NV, DuPont Nutrition & Health, BASF, and Abbott to expand their HMO ingredient offerings.PR NewswireThe global human milk oligosaccharides (HMO) market size is expected to reach USD 71.2 billion by 2025A new report by Grand View Research projects the global human milk oligosaccharides (HMO) market will reach USD 71.2 billion by 2025, growing at a CAGR of 21.9%, driven by rising infant health awareness and increasing investments in emerging economies. The infant formula segment is expected to witness the fastest growth at a 22.0% CAGR, while North America held over 80% market share in 2017. Key industry players including DuPont, BASF, Abbott, and Inbiose NV have recently launched HMO-based products or formed partnerships to capitalize on market growth.PR NewswireHuman Milk Oligosaccharides Market Analysis By Application And Segment Forecasts To 2024Grand View Research released a market report projecting the global human milk oligosaccharides (HMO) market to reach USD 170.4 million by 2024, driven by growing application in infant formula and functional beverages. The report identifies Europe as the largest regional market in 2015 and cites declining infant mortality rates and rising disposable income in emerging economies as key growth drivers. Specific industry developments include Inbiose NV initiating the CARBOSURF project in July 2015 and Madolac Laboratories completing the second phase of its HMO purification plant in October 2014.